Atara Biotherapeutics (AT20) Stock Price & Analysis
AT20 Stock Chart & Stats
- Day’s Range
- EUR 7.30 - EUR 7.40
- 52-Week Range
- EUR 3.48 - EUR 16.30
- Previous Close
- EUR 7.70
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 71.99M
- Enterprise Value
- EUR 214.12M
- Total Cash (Recent Filing)
- EUR 9.87M
- Total Debt (Recent Filing)
- EUR 9.88M
- Price to Earnings (P/E)
- ―
- Beta
- 1.00
- Next Earnings
- Mar 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress
FDA acceptance advances tabelecleucel into a defined regulatory review with a target action date, creating a concrete path toward potential approval. This could convert Atara’s clinical-stage platform into a partnered commercial opportunity and support future milestone and royalty economics.
Partnered Commercial Economics
The Pierre Fabre agreement gives Atara access to milestone payments and significant tiered royalties without requiring Atara to build the entire commercial infrastructure itself. If approval and sales milestones are achieved, this structure could provide scalable non-product revenue.
Off-the-Shelf T-Cell Platform
An allogeneic, off-the-shelf approach is designed around readily available cell therapies rather than individually manufactured treatments. Its focus across EBV-associated cancers, tumor antigens, and engineered CAR T programs provides a platform foundation for multiple potential therapeutic applications.
Bears Say
Sharp Revenue Deterioration
The steep TTM revenue decline and return to a sizable loss indicate that recent earnings power has not been sustained. For a clinical-stage company dependent on collaborations and milestones, volatile revenue makes operating performance less predictable and increases reliance on future development outcomes.
Negative Shareholders’ Equity
Persistently negative equity signals a weakened capital structure and reduces financial flexibility. Combined with reported debt and ongoing losses, it can make funding growth or absorbing setbacks more difficult, while increasing dependence on external financing to support continued development.
Ongoing Cash Burn
Negative operating and free cash flow across the periods shows that the business is not currently self-funding its operations. Continued cash burn can require additional financing, potentially increasing dilution risk and limiting the resources available for clinical development and regulatory execution.
Atara Biotherapeutics News
Atara Biotherapeutics Defendants Move to Dismiss Amended Securities Class Action Over Tab-cel FDA Rejection
Atara Biotherapeutics, Inc. ($ATRA) and four of its current and former executives have asked a federal court to dismiss an amended securities class action complaint that accuses them of misleading
AT20 FAQ
What was Atara Biotherapeutics’s price range in the past 12 months?
What is Atara Biotherapeutics’s market cap?
When is Atara Biotherapeutics’s upcoming earnings report date?
How were Atara Biotherapeutics’s earnings last quarter?
Is Atara Biotherapeutics overvalued?
Does Atara Biotherapeutics pay dividends?
What is Atara Biotherapeutics’s EPS estimate?
How many shares outstanding does Atara Biotherapeutics have?
What happened to Atara Biotherapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Atara Biotherapeutics?
What is the TipRanks Smart Score and how is it calculated?
Atara Biotherapeutics Stock Smart Score
Company Description
Atara Biotherapeutics
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Anhco Nguyen
- Employees
- 10
- Website
- www.atarabio.com
- Address
- 1280 Rancho Conejo Blvd, Thousand Oaks, CA, 91320, US
Atara Biotherapeutics (AT20) Earnings & Revenues
AT20 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 3 | 13 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 1 | 0 | 11 |
